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Abstract Advanced basal cell carcinomas are a subset of
basal cell carcinomas that can be difficult to treat either due
to their local invasiveness, proximity to vital structures, or
metastasis. The incidence of all basal cell carcinoma is in-
creasing in the United States, although it is not knownwhether
advanced basal cell carcinomas (aBCCs) are also increasing.
Recently, highly targeted therapy based on knowledge of the
basal cell carcinoma pathogenesis has become available either
commercially or through human clinical trials. These orally
available drugs inhibit the Hedgehog signaling pathway, and
lead to advanced basal cell carcinoma shrinkage that can
enable preservation of adjacent vital organs. In this review,
we outline the role of Hedgehog pathway inhibitors as well as
other treatment modalities such as excision, radiotherapy and
more traditional chemotherapy in treating advanced basal cell
carcinomas. We also highlight current gaps in knowledge
regarding the use and side effects of this targeted therapy.
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Introduction
The recent introduction of targeted therapy for advanced basal
cell carcinomas (aBCCs) in the form of Hedgehog signaling
pathway inhibitors represents one of the greatest triumphs of
translational medicine, bridging basic science of a conserved
developmental pathway with clinical application in patients
with difficult-to-treat skin cancers [1, 2, 3, 4, 5]. In the coming
years, the number of agents in this drug class is expected to
increase. These drugs will be a powerful tool to complement,
or in some cases substitute, for traditional treatment modalities
for aBCCS, such as excision or radiotherapy.
Epidemiology
BCC comprises the majority of non-melanoma skin cancers
(NMSCs) and is more common than all other human malig-
nancies combined. Several lines of evidence suggest that the
worldwide incidence of BCCs is increasing. In the United
States, the diagnosis and treatment of NMSCs has increased
dramatically with a growth rate of 77 % over the past two
decades. The fastest growing group is in women under the age
of 40 years [6, 7]. In other countries such as Singapore where
incidence of BCCs is monitored, the rate of BCCs has been
rising over the past several decades as well [8]. Overall, the
reasons for this dramatic growth have been postulated to
include the aging population, changes in sun exposure habits,
environmental changes, migration patterns, and to a
lesser extent, increased prevalence of immunosuppressant
use [9, 10].
More than 2.8 million new cases of BCC are diagnosed
each year in the United States alone, and are estimated to
result in over 3,000 deaths [1]. Fortunately, BCCs are usually
diagnosed early and treated [11]. Nevertheless, a recent large,
retrospective analysis from a major academic center reported
5-year recurrence rates at 2–3 % [12]. Given the high inci-
dence of BCCs, this recurrence rate results in a large number
of BCCs that are not cured by surgical excision. Furthermore,
BCCs that are extensive and infiltrate structures below the
skin or abut vital structures such as the brain or eyes may be
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difficult to surgically clear without significant morbidity.
Many of these may become locally advanced or metastasize.
BCCs that metastasize to either local or distant lymph nodes
or distant organs would best be addressed through systemic
therapy. Together, these locally advanced or metastatic BCCs
comprise a disease group termed “advanced BCCs” (aBCCs).
While accurate estimates of the incidence of aBCCs are
difficult to obtain, in part due to the lack of widespread use of
a staging system by dermatologists and lack of uniform
reporting requirements for NMSCs, aBCCs are thought to
represent roughly 1–10 % of all BCCs, with metastatic BCCs
accounting for 0.0028–0.5 % [13–15]. From our clinical ex-
perience, patients presenting with aBCCs appear to fall into
two categories, (1) those who present with aBCC due to delay
in accessing medical attention; or (2) those who have BCCs
that are intrinsically aggressive and are refractory or recur after
treatment.
Economic, Physical and Psychosocial Impact of Advanced
BCCs
NMSCs including BCCs account for 4.5 % of Medicare
cancer expenditures, making it the fifth most costly cancer to
treat [16, 17]. From 2005 to 2008, NMSCs accounted for $2.9
billion in average annual expenditures on cancer conditions
among adults in the U.S. While aBCCs are uncommon, their
size and location may require excision in the operating room
with specialized surgical teams and postoperative hospital
stays, likely leading to far greater medical costs than operable
BCCs that can be managed in the office setting. When non-
surgical modalities are utilized in aBCCs, such as radiation or
chemotherapy, the cost of treating aBCCs rises dramatically,
although there are no studies to date that have formally quan-
titated this. Therapeutic innovations such as Hedgehog path-
way inhibitors may improve quality of life and extend the
length of productive lifespan in some patients; however, this
treatment has a significant financial cost, as a one-month
supply of vismodegib currently exceeds $7,500. Patients
who respond to the drug and tolerate side effects may be on
this drug indefinitely, as currently there is insufficient data as
to when this drug might be discontinued, heightening long-
term costs.
Exploratory studies into the physical and psychosocial
impact of advanced BCCs are underway; however, the disease
can be challenging to characterize, in part due to variable
progression and rarity of the disease [18, 19]. Anecdotal
evidence from our clinical experience suggests that aBCC
patients are subject to significant physical and psychological
burden. Physical burdens including pain, blood loss with
anemia and fatigue, infection risk with open wounds, limita-
tions in movement or function due to location of aBCCs and
side effects of surgery, radiation or chemotherapy.
Psychosocial burdens from aBCC disease include depression,
anxiety, social isolation, depleted financial resources from
treatments, inability to find or maintain employment or inabil-
ity to provide for or care for dependent family members. Even
patients whose disease is stable or successfully treated can
have significant limitation in functional ability due to scarring,
disfigurement, and/or chronic pain.
Life expectancy in aBCC patients also contributes to the
economic impact of this disease. Historically, reports of sur-
vival after diagnosis of distant metastasis in BCC patients
were grim, estimated at 8–14 months [20]. A more recent
retrospective case series from 1997–2011 suggested markedly
improved survival in patients followed at a tertiary care center,
with median survival time of 7 years [13]. Future analysis will
be needed to identify factors that contribute to survival time,
and the financial cost of any treatments associated with sur-
vival prolongation.
Therapeutic Innovation of Advanced BCC Treatment
Historically, treatment options available to patient with
aBCCs were not necessarily based on an understanding of
the molecular characteristics of BCC pathogenesis. Treatment
options included surgery, radiation, and traditional chemother-
apies such as cisplatin-based treatment, but without systematic
trials to follow for efficacy and safety, in part due to the rarity
and heterogeneity of the condition (Table 1). In essence, there
was no clearly established or superior treatment modality for
aBCCs.
In the 1990s, the connection between aberrations of the
Hedgehog signaling pathway and BCCs in mice was made
[21•]. Around the same time, multiple studies connected this
pathway in humans with both sporadic BCCs and an autosomal
dominant genetic syndrome predisposing to multiple BCCs,
basal cell nevus syndrome (BCNS) or Gorlin-Goltz syndrome
[22]. The majority of mutations in sporadic BCCs and BCNS
patients occur in PTCH1 [23, 24], a protein that inhibits
Smoothened. BCNS patients experience early onset and nu-
merous BCCs, due to loss-of-heterozygosity in the PTCH1
gene. The second most common mutation in sporadic BCCs
and BCNS patients are gain-of-function mutations of the
Smoothened gene [25, 26]. Loss of PTCH1 results in the lack
of Smoothened inhibition, leading to increases in GLI1 levels,
changes in transcription, and subsequent tumorigenesis. Gain-
of-function Smoothenedmutations also leads to increasedGLI1
levels and tumorigenesis [27]. A simplified schematic of the
Hedgehog (Hh) pathway is presented in Fig. 1a.
The story of how the first inhibitor of the Hh pathway,
cyclopamine, was discovered is one of the most fascinating in
biomedicine. In the 1960s, pregnant ewes ingesting the Cali-
fornia corn lily were found to produce one-eyed offspring, or
extreme holoprosencephaly [28]. In the 1970s, the active
Curr Derm Rep (2014) 3:40–45 41
agent inducing these changes, cyclopamine, was isolated and
its structural formula identified. Subsequent studies in the
1990s in chick embryos demonstrated cyclopamine’s ability
to induce holoprosencephaly and to bind the transmembrane
protein, Smoothened [29]. Subsequently, a number of ana-
logues were developed by modifications to cyclopamine to
improve solubility, and oral bioavailability. Collectively, these
analogues are called Smoothened inhibitors (SIs), due to their
targeting of the Smoothened protein (Fig. 1b).
Multiple orally available SIs are currently in human clinical
trials against BCCs. The first and only U.S. Food and Drug
Administration (FDA) approved SI for aBCCs to date is
vismodegib, which became commercially available in 2012.
The phase II study with 96 aBCC patients leading to FDA
approval demonstrated an independently assessed response
rate of 30 % in patients with metastatic BCC and 43 %
response rate in locally advanced BCC [30••]. A subsequent
study of 119 aBCC patients showed similar findings [31]. The
availability of vismodegib as highly targeted therapy for
aBCCs is one of the greatest success stories in translational
medicine.
While most SIs in human trials come from the research
pipelines of pharmaceutical companies, two existing FDA
approved drugs have shown activity against the Hh pathway.
These are oral ketoconazole and intravenous arsenic trioxide,
both of which are being been tested in mouse models [32•]
and a small number of BCC patients in the research setting,
with results currently unpublished.
Role of Smoothened inhibitors in Advanced BCC
Treatment
Along with innovation in therapy come many questions that
remain to be answered. First, which aBCC patients are appro-
priate for SI treatment? An example clinical decision tree is
shown in Fig. 2. However, given the heterogeneity of aBCC
patients as far as tumor location and extent and comorbidities,
each patient should be considered on a case-by-case basis, in
conjunction with multidisciplinary consultation such as med-
ical oncology, radiation oncology and surgical specialties. In
addition, patients may have differential tolerance for side
effects of SIs. As a class, these side effects include muscle
spasms, taste disturbance, alopecia, nausea, and fatigue [33].
Anecdotally, muscle spasms have been ameliorated with mus-
cle relaxants such as cyclobenzaprine. Nausea and poor oral
intake have been addressed with megestrol acetate or
dronabinol. SIs are also potent teratogens and two forms of
medically reliable birth control should be used in patients (and
their partners) with reproductive potential. Patients on SI
treatment need to follow closely with their treating physicians
to monitor for tumor response and side effects. In addition to
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imaging to monitor for disease recurrence in cases where the
aBCC has a deep component or is metastatic to non-skin
organs. If the aBCC is refractory or recurrent, timely interven-
tion with other treatment modalities is critical.
Second, can the response rate for aBCCs be increased
when combined with other treatment modalities, such as
other chemotherapies or radiation treatment? Can recur-
rence rates be decreased when combined with other treat-
ment modalities? Clinical trials are underway to explore
these questions.
Third, what is the impact of SI treatment on progression
free survival or overall survival in aBCCs? Given the rarity of
this disease, multicenter registry studies are in progress to
assess these.
Fourth, what is the impact of SI treatment on quality of life
and psychosocial outcomes? The impact of SI treatment re-
lates to the efficacy of the drug against the aBCC, as well as
the tolerability of the side effects. Compared to many other
forms of chemotherapy, the side effects of SI may be more
tolerable. Alternatively, muscle spasms or other side effects
may limit the ability of patients to take the drug in the long
term, and/or maintain a good quality of life despite disease
stabilization. Patient-based instruments recently have been
developed to better assess these endpoints [18, 19].
Fig. 2 Example treatment
algorithm for advanced basal cell
carcinoma. Due to disease
heterogeneity in advanced basal
cell carcinomas, actual treatment
depends on tumor location, prior
treatments and patient
comorbidities
Gain of function 
mutation of SMO
Loss of function 































Fig. 1 Simplified schematic of
common mutations in the
Hedgehog signaling pathway
leading to basal cell carcinoma
from pathway activation (a), and
therapeutic targets of this
pathway (b)
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Fifth, are there clinical predictors for response to SI treat-
ment? One analysis from an expanded access study in patients
for vismodegib identified prior treatment with systemic ther-
apy as negatively correlated with laBCC response in 56 pa-
tients [34]. There was no association with age, prior radiother-
apy or number of sites affected with aBCCs. In this same
study, analysis of 39metastatic BCCs showed that neither age,
prior radiotherapy, prior systemic therapy or number of sites
affected with aBCCs were associated with tumor response.
Larger prospective studies are underway to assess clinical
predictors for SI response.
Sixth, are there tumor markers from biopsies to predict
response to SI treatment? Given the aggressiveness of
many aBCCs, the decision of which treatment modality
to undertake could be life-saving. Current studies are un-
derway to assess for mutations, gene expression changes or
protein levels within the Hh signaling pathway [35–37]
that could correlate with response or lack of response, with
the ultimate goal of assisting with clinical decision-
making. As the current cost of SI drugs is quite high, a
diagnostic test that could indicate the likelihood of re-
sponse to these drugs may be cost effective.
Many additional issues remaining to be clarified regarding
the use of SIs, including: effective management of common
side effects, long-term side effects such as the potential for
secondary cancers, whether there is differential response
based on BCC subtype, when SI treatment may be safely
discontinued after apparent complete clinical response, and
whether SIs should be used to treat microscopic disease in
surgical cases where margins are positive.
Conclusion
Advanced BCCs are often difficult to treat and life-
threatening. SI drugs can be life-saving in many cases, though
disease progression or recurrence is a major concern that
requires regular monitoring through skin examinations and/
or radiologic imaging. Successful management of side effects
is critical to continued treatment with these drugs. When
aBCCs are refractory, achieve a partial response, or are recur-
rent after SI therapy, other treatment modalities such as radi-
ation, traditional chemotherapy or surgical excision need to be
considered for optimum patient outcomes.
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